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Abstract
Background: Diagnostics and research of high-consequence animal disease agents is often limited to laboratories
with a high level of biosecurity that restrict the transport of biological material. Often, sharing of DNA with external
partners is needed to support diagnostics, forensics, or research. Even in the absence of virus, RNA from positive-sense
single stranded RNA (+ssRNA) viruses that may contaminate otherwise purified DNA preparations continues to pose a
threat due to its potential to be infectious via direct translation to yield viral proteins. While the risk of animal infection
or accidental reconstitution and release of a virus from RNA is very low, the high impact of an animal disease event
associated with the accidental release of some + ssRNA viruses, such as classical swine fever or foot-and-mouth disease
viruses, necessitates the precaution of having procedures to ensure the complete inactivation of viruses and + ssRNA
viral genomes. RNA and DNA are differentially susceptible to enzymatic degradations; however, such procedures
are susceptible to unintended DNA damage and/or failure due to enzyme or cofactor instabilities. Therefore, we
describe the development and verification of a robust and simple chemical and physical method to selectively
degrade RNA from purified DNA preparations. The procedure employs incubation of DNA in 0.25 N sodium
hydroxide at 65 °C for 1 h followed by neutralization and boiling for 10 min to hydrolyze contaminating RNA
and inactivate animal disease viruses from DNA preparations. Additional critical quality control elements include
use of a synthetic control RNA (SCR) and an SCR-specific real-time RT-PCR to track effectiveness of the procedure
in a parallel treated control sample, and a pH check of reagents to ensure proper neutralization of alkaline
conditions.
Results: The new procedure reduced intact RNA beyond the limit of detection by realtime RT-PCR and inactivated
viruses by in vitro culture infectivity assays.
Conclusions: Treated DNA, while denatured, remains suitable for most common molecular biology procedures including
PCR, transformation of E. coli, and molecular sequencing. The procedure ensures not only the inactivation of a variety of
viruses but also the degradation through hydrolysis of potentially contaminating infectious + ssRNA viral genomes.
Background
Positive-sense single stranded RNA (+ssRNA) viruses of
agricultural and economic importance include agents
such as foot-and-mouth disease virus (FMDV) and
classical swine fever virus (CSFV). FMDV is a highly
contagious disease of cloven-hoofed animals including
cattle, swine, sheep, goats, and various wildlife species.
FMDV is a non-enveloped virus belonging to the genus
Aphthovirus in the family Picornaviridae. There are
seven known serotypes of FMDV including types A, O,
C, Asia1, South African Territories (SAT) 1, SAT2, and
SAT3 [1]. Although mortality in adult animals is low, its
wide distribution, high transmission rates, and broad
host range in livestock make it one of the leading threats
to animal agriculture, reviewed in [2]. CSFV is another
highly contagious disease of livestock, affecting specific-
ally swine and wild boars, and belonging to the genus
Pestivirus in the family Flaviviridae [3]. Although there
is only one known serotype of CSFV, several strains ran-
ging in virulence have been identified, some with high
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mortality rates, reviewed in [4]. Both FMDV and CSFV
can result in high-consequence animal disease outbreaks
with significant economic losses in livestock industries
and trade and are reportable to the World Organization
of Animal Health (OIE). Consequently, diagnostics
and research on such high-consequence animal disease
pathogens is typically limited to laboratories with a high
level of biosecurity and restricted permissible transport of
biological materials out of the laboratory. Such precau-
tions include the export of purified nucleic acids.
Even in the absence of virus, RNA from + ssRNA vi-
ruses continues to pose a threat to agricultural industries
due to its potential to be infectious via direct translation
yielding viral proteins [5]. For instance, transfection
studies employing DNA contaminated with RNA from +
ssRNA viruses can inadvertently result in the expression
of infectious virus. Often, however, the sharing of DNA
with external partner laboratories is needed to support
diagnostics, forensics, or research and development ac-
tivities. For example, non-infectious DNA samples, such
as human DNA associated with forensic samples from
an animal disease investigation, might need to be shared
with a criminal investigation laboratory. Alternately, a
portion of complementary DNA (cDNA) or DNA from a
virus may need to be sent, either directly or cloned into
plasmid DNA, to another laboratory as an experimental
reagent. Because these DNA materials originate from a
biocontainment laboratory that works with + ssRNA vi-
ruses of high-consequence, trace amounts of virus or
even viral RNA present concerning sources of potentially
infectious contamination that must be mitigated prior to
the transport of DNA outside of biocontainment.
Due to subtle differences in the structures of RNA and
DNA, including a hydroxyl group on the 2’-carbon atom
of the phosphopentose backbone of RNA, RNA reactiv-
ity and stability under certain conditions is fundamen-
tally different than that of DNA [6]. For example in the
early 1900’s, shortly after the discovery of RNA and
DNA, the instability of RNA and contrasting stability of
DNA under basic conditions was recognized. This fun-
damental biochemical property of RNA formed the basis
of widely established alkaline treatment methods for the
purification of free or partially hydrolyzed ribonucleo-
tides from RNA [7], and modern methods of degrading
RNA in labeling or stripping of DNA microarrays or in
advanced molecular sequencing protocols [8–11]. In
contrast, the stability of ssDNA under alkaline condi-
tions formed the basis for the alkaline lysis method of
plasmid DNA purification from bacteria [12]. RNA is
uniquely unstable in alkaline conditions because bases
can easily deprotonate the hydrogen from the hydroxyl
group on the 2’-carbon atom (Fig. 1). This deprotonation
causes the oxygen to become negatively charged leading
to a nucleophilic attack on the adjacent phosphate atom
leading to the cleavage of the phosphopentose backbone
of RNA. The resultant 2',3'-cyclic phosphate is further
hydrolyzed to 2' or to 3' phosphate leaving RNA frag-
ments or free ribonucleotides with 5’-OH and 3’-
Fig. 1 Schematic of RNA degradation under extreme alkaline pH conditions. a The phosphopentose backbone of RNA is shown. b The 2’ hydroxyl
(OH) of RNA becomes deprotonated under extreme alkaline conditions leading to a nucleophilic attack on the 5’ phosphate (PO4) of the adjacent
nucleotide. c An intermediate 2’,3’ cyclic phosphate is formed resulting in, d cleavage of the phosphopentose backbone of RNA. The resultant 2’,3’-
cyclic phosphate may be further hydrolyzed to 2' or to 3' phosphate leaving RNA fragments or free ribonucleotides with 5’-OH and 3’-phosphates
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phosphates, depending on the level of degradation
(Fig. 1). Conversely the lack of a 2’-OH in DNA prevents
cleavage of the phosphate backbone making DNA rela-
tively stable at high pH. As this autocatalytic degradation
is a property of the RNA phosphopentose backbone it-
self, the use of alkaline pH combined with heat treat-
ment has been used to selectively degrade RNA from
RNA:DNA or RNA:cDNA hybrids [10, 11, 13].
While RNA and DNA are also differentially susceptible
to enzymatic degradations, such procedures may cause
unintended DNA damage and/or fail due to enzyme or
cofactor instabilities. This paper aims to describe the
development and verification of a robust and simple
chemical method to selectively degrade RNA. The pro-
cedure is demonstrated to be useful in the inactivation
of viruses and the removal of RNA, including potentially
infectious viral + ssRNA, from a purified DNA sample.
Extreme alkaline (0.25 N NaOH at pH > 12) and heat
treatment were chosen as the basis of the new DNA
safety treatment method based on the well-established
property of RNA degradation and ssDNA stability under
alkaline conditions, previously established sensitivity of
high-consequence animal disease viruses to heat inacti-
vation by boiling for 5 min, and documented inactiva-
tion of FMDV and CSFV at alkaline pH. In this regard,
FMDV is inactivated at pH levels less than 6 and greater
than 9 [14], and CSFV is known to be inactivated at pH
levels less than 3 and greater than 11 [15]. While alka-
line or heat treatment are both individually expected to
denature dsDNA, this procedure, based on the verifica-
tion studies presented herein and earlier studies on heat
inactivation of animal disease viruses [16, 17], may form
the basis for inactivation of potentially contaminating vi-
ruses and the robust degradation of viral + ssRNA from
purified DNA. Following alkaline and heat treatment,
the denatured DNA remains suitable for recovery by
precipitation and manipulation in routine molecular
biology procedures such as transformation of E.coli and
molecular sequencing.
Results
DNA integrity and loss of RNA
Integrity of DNA, such that safety treated DNA remains
intact, unmodified, and suitable for manipulation in
most routine molecular biology procedures, was an im-
portant criteria in the development of the alkaline and
heat DNA safety treatment procedure. While, alkaline
and heat treatment are both individually expected to de-
nature dsDNA, confirming minimal single stranded
nicks and double strand breaks was deemed important
for downstream applications such as bacterial transform-
ation of plasmids, PCR, and DNA sequencing.
DNA integrity and loss of RNA was evaluated by agar-
ose gel electrophoresis, rRT-PCR, and sequencing. Various
samples including, plasmid and/or CSFV and African
swine fever virus (ASFV) PCR amplified cDNA or DNA,
CSFV RNA, and/or synthetic control RNA (SCR) spiked
samples after NaOH and heat treatment, heat treatment
alone, or no treatment as control were evaluated.
Table 1 addresses initial studies aimed at verification
of RNA degradation while maintaining plasmid DNA in-
tegrity using a NaOH and heat treatment incubation
time of 30 min as compared to the later determined op-
timal treatment time of 60 min. CSFV RNA and SCR
spiked samples containing plasmid DNA were tested in
various conditions ranging from untreated control
samples to safety treated plasmid DNA samples contain-
ing SCR as an internal control and CSFV RNA as a sim-
ulated contaminant (Table 1). All positive controls
(untreated, heat only treatment, or 250 mM NaCl con-
taining samples) for both SCR RNA and CSFV RNA
tested positive by rRT-PCR for their respective targets
(Table 1). All negative controls (water or samples with
no target added) tested negative for SCR and CSFV
RNA by rRT-PCR (Table 1). All safety treated samples
tested negative by SCR and CSF rRT-PCRs for their re-
spective targets with the exception of sample 4, suggest-
ing that the time of incubation for NaOH and heat
treatment could be further optimized. Plasmid DNA
integrity was maintained with some slight nicking and
denaturation to ssDNA as visualized by agarose gel elec-
trophoresis (data not shown).
Table 2 and Fig. 2 address safety treatment optimization
studies aimed at verifying SCR degradation while main-
taining viral and plasmid DNA integrity using NaOH and
heat treatment incubation times of 30, 45 and 60 min.
CSFV cDNA, plasmid and ASFV DNA samples were
tested in various conditions ranging from untreated con-
trol samples to safety treated DNA samples all containing
SCR internal controls (Table 2). All positive controls (un-
treated, heat only treatment or diluted samples) tested
positive by SCR rRT-PCR. SCR was not degraded beyond
the level of rRT-PCR detection during the safety
treatment process for the 30 and 45 min incubations
at 65 °C in 0.25 N NaOH as indicated by positive
SCR rRT-PCR results (Table 2). All SCR RNA sam-
ples incubated for 60 min at 65 °C tested negative for
SCR RNA by rRT-PCR (Table 2).
All ASFV DNA samples, controls and treatment sam-
ples retained intact DNA. This was verified by ASF rPCR
in all samples, with the exception of samples 10 and 13
that yielded anomalous rPCR amplification dynamics due
to high ASFV DNA template concentrations (Table 2). All
CSFV cDNA samples likewise tested positive by CSF rRT-
PCR, indicating DNA integrity was maintained through-
out the process (Table 2). Plasmid DNA integrity was
maintained with some slight nicking and/or denaturation
of ssDNA as indicated by supercoiled untreated plasmid
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DNA and less sharp banding with slightly slow mobility
on agarose gel electrophoresis (Fig. 2). No significant dif-
ference in the integrity of CSFV cDNA, plasmid, or ASFV
DNA was apparent regardless of the time of incubation
for alkaline hydrolysis; therefore, 60 min was selected as
the optimal time of alkaline and heat hydrolysis to ensure
complete degradation of all RNA (Table 2 and Fig. 2).
Effects on bacterial transformations
Transformation efficiency of alkali and heat treated DNA
was evaluated using E. coli strains DH5 alpha, JM109, and
BL21. Alkali and heat safety treated pBlueScript II plas-
mid, or untreated plasmid as control, were used to trans-
form bacteria using a variation of the heat shock method
[18]. Each bacterial strain readily yielded transformants,
albeit efficiencies were reduced by 6.6 to 54.8 fold as com-
pared to transformations with untreated plasmid. Blue
white colony screening by alpha complementation was
used with the DH5 alpha strain to demonstrate proper ex-
pression and function of the plasmid encoded LacZ gene
product before and after alkali and heat safety treat-
ment. In this regard, all bacterial DH5 alpha colonies
were blue suggesting a lack of significant mutation
leading to loss in expression or function of the alpha
peptide of β-galactosidase.
Sequencing of DNA post alkaline and heat hydrolysis of
RNA
FMDV cDNA integrity was analyzed by sequencing of
the P1 region of the FMDV genome. Maintenance of
DNA integrity is important to ensure successful per-
formance of downstream applications. Table 3 and Fig. 3
address downstream application studies aimed at verifi-
cation of DNA integrity by FMDV sequencing of the P1
region of the genome. FMDV cDNA samples were tested
in various conditions ranging from untreated control
Table 1 Verification of RNA degradation while maintaining plasmid DNA integrity
Sample ID Heat Plasmid CSFV RNA SCR NaOH HCl TE PCR DNA
1- SCR RNA x 0 μl 0 μl 26 μl 0 μl 0 μl 260 μl SCR+, CSF- NA
2- Plasmid DNA x 130 μl 0 μl 0 μl 0 μl 0 μl 156 μl SCR-, CSF- +
3- SCR RNA/Plasmid DNA x 130 μl 0 μl 26 μl 0 μl 0 μl 130 μl SCR+, CSF- +
4- SCR RNA treated x 0 μl 0 μl 26 μl 60 μl 60 μl 140 μl SCR+, CSF- NA
5- Plasmid DNA treated x 130 μl 0 μl 0 μl 60 μl 60 μl 36 μl SCR-, CSF- +a
6- SCR RNA/Plasmid DNA treated x 130 μl 0 μl 26 μl 60 μl 60 μl 10 μl SCR-, CSF- +a
7- CSF RNA x 0 μl 10 μl 0 μl 0 μl 0 μl 276 μl SCR-, CSF+ NA
8- CSF RNA/SCR RNA x 0 μl 10 μl 26 μl 0 μl 0 μl 250 μl SCR+, CSF+ NA
9- CSF RNA/SCR RNA/ Plasmid DNA x 130 μl 10 μl 26 μl 0 μl 0 μl 166 μl SCR+, CSF+ +
10- CSF RNA/Plasmid DNA x 130 μl 10 μl 0 μl 0 μl 0 μl 140 μl SCR-, CSF+ +
11- CSF RNA treated x 0 μl 10 μl 0 μl 60 μl 60 μl 130 μl SCR-, CSF- NA
12- CSF RNA/SCR RNA treated x 0 μl 10 μl 26 μl 60 μl 60 μl 156 μl SCR-, CSF- NA
13- CSF RNA/SCR RNA/ Plasmid DNA treated x 130 μl 10 μl 26 μl 60 μl 60 μl 0 μl SCR-, CSF- +a
14- CSF RNA/Plasmid DNA treated x 130 μl 10 μl 0 μl 60 μl 60 μl 260 μl SCR-, CSF- +a
15- SCR RNA post pH normalization x 0 μl 0 μl 26μlb 60 μl 60 μl 146 μl SCR+, CSF- NA
16- Plasmid DNA post pH normalization x 130 μlb 0 μl 0 μl 60 μl 60 μl 36 μl SCR-, CSF- +
17- CSF RNA post pH normalization x 0 μl 10 μlb 0 μl 60 μl 60 μl 130 μl SCR-, CSF+ NA
18- CSF RNA/SCR RNA post pH normalization x 0 μl 10μlb 26μlb 60 μl 60 μl 156 μl SCR+, CSF+ NA
19- CSF RNA/SCR RNA/Plasmid DNA post pH normalization x 130μlb 10μlb 26μlb 60 μl 60 μl 0 μl SCR+, CSF+ +
20- CSF RNA undilute control 0 μl 2.5 μl 0 μl 0 μl 0 μl 0 μl SCR-, CSF+ NA
21- CSF RNA diluted control 0 μl 10 μl 0 μl 0 μl 0 μl 276 μl SCR-, CSF+ NA
22- SCR RNA diluted control 0 μl 0 μl 26 μl 0 μl 0 μl 260 μl SCR+, CSF- NA
23- SCR RNA undilute control 0 μl 0 μl 2.5 μl 0 μl 0 μl 0 μl SCR+, CSF- NA
24- CSF positive amplification control 0 μl 2.5 μl 0 μl 0 μl 0 μl 0 μl SCR-, CSF+ NA
25- No template control for PCR 0 μl 0 μl 0 μl 0 μl 0 μl H2O SCR-, CSF- NA
Samples, containing various combinations of SCR RNA, CSF RNA, and pGEM Teasy Vector plasmid, treatment conditions, and results for verification of RNA
degradation and maintenance of plasmid DNA integrity are listed. NaOH and heat treatment incubation time used in this initial study was 30 min. aSlight nicking
or denatured to ssDNA was observed as compared to untreated control plasmid. bReagent added post pH neutralization as a positive control sample. NA indicates
not analyzed; x indicates 60 °C incubation and 10’ boiling steps were included
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samples to safety treated DNA samples incubated at the
optimized incubation time of 60 min (Table 3). All
FMDV cDNA samples, including untreated, heat only
treated, and alkali and heat treated samples were suc-
cessfully sequenced at comparable coverage (Fig. 3). All
high quality DNA sequences appeared to be identical in
comparisons to untreated control FMDV cDNA.
Inactivation of viruses post alkaline and heat hydrolysis
of RNA or boiling
Virus isolation was performed to ensure inactivation of
FMDV and CSFV during the NaOH and heat DNA
safety treatment process which included a final 10 min
boiling step. Table 4 addresses studies aimed at verifica-
tion of the inactivation of infectious FMDV and CSFV
by heat only treatment (65 °C for 1 h followed by boiling
for 10 min) or the complete NaOH and heat safety treat-
ment using infectivity assays in primary LK or the SK-6
cell line, respectively. FMDV and CSFV spiked samples
were tested under various conditions ranging from un-
treated, heat only and NaOH and heat safety treatment
(Table 4). All positive controls (untreated and unheated,
undilute or virus in diluents: TE, salt, or water) tested
positive for cytopathic effect for FMDV and by immuno-
histochemical staining for CSFV (Table 4). All heat only
Table 2 Optimization of RNA hydrolysis while maintaining viral and plasmid DNA integrity
Sample ID Heat (min) DNA SCR RNA NaOH HCl TE SCR PCR ASF PCR CSF PCR DNA integrity
1- ASF DNA control 0 35 μl 7 μl 0 μl 0 μl 30 μl + + NA +
2- CSF DNA control 0 35 μl 7 μl 0 μl 0 μl 30 μl + NA + +
3- Plasmid DNA control 0 35 μl 7 μl 0 μl 0 μl 30 μl + NA NA +
4- ASF DNA heated 30 35 μl 7 μl 0 μl 0 μl 30 μl + + NA +
5- CSF DNA heated 30 35 μl 7 μl 0 μl 0 μl 30 μl + NA + +
6- Plasmid DNA heated 30 35 μl 7 μl 0 μl 0 μl 30 μl + NA NA +
7- ASF DNA treated 30 35 μl 7 μl 15 μl 15 μl 0 μl - + NA +
8- CSF DNA treated 30 35 μl 7 μl 15 μl 15 μl 0 μl + NA + +
9- Plasmid DNA treated 30 35 μl 7 μl 15 μl 15 μl 0 μl + NA NA +a
10- ASF DNA treated 45 35 μl 7 μl 15 μl 15 μl 0 μl - Incb NA +
11- CSF DNA treated 45 35 μl 7 μl 15 μl 15 μl 0 μl + NA + +
12- Plasmid DNA treated 45 35 μl 7 μl 15 μl 15 μl 0 μl - NA NA +a
13- ASF DNA treated 60 35 μl 7 μl 15 μl 15 μl 0 μl - Incb NA +
14- CSF DNA treated 60 35 μl 7 μl 15 μl 15 μl 0 μl - NA + +
15- Plasmid DNA treated 60 35 μl 7 μl 15 μl 15 μl 0 μl - NA NA +a
16- SCR in TE 0 0 μl 7 μl 0 μl 0 μl 65 μl + NA NA NA
17- SCR in salt 0 0 μl 7 μl 15μlc 15μlc 35 μl + NA NA NA
18- SCR undilute control 0 0 μl 2.5 μl 0 μl 0 μl 0 μl + NA NA NA
Samples containing various combinations of ASF DNA, CSF cDNA, and plasmid DNA, under various treatment conditions. All samples contained SCR, and results
for verification of SCR degradation and maintenance of plasmid DNA integrity are listed. NaOH and heat treatment incubation time used in this study range from
0 to 60 min. Following heat treatment for various times at alkaline pH, all samples were boiled for 10 min at neutral pH. aSlight nicking or denatured ssDNA was
observed as compared to untreated control plasmid. bInconclusive rPCR result (Inc) due to high concentration of DNA template. cNeutralized salt solution (equal
parts 1 N NaOH and 1 N HCl) reagent used as a positive control. NA indicates not analyzed
Fig. 2 Plasmid DNA integrity following alkaline and heat treatment.
Imaging of pGEM Teasy plasmid DNA samples as visualized by gel
electrophoresis. Safety treated DNA samples are shown following
incubation in 0.25 N NaOH at 65 °C for 30, 45 and 60 min followed
by neutralization of pH and incubation at 100 °C for 10 min (lanes 2,
3 and 4, respectively). Controls consisted of heat only treated DNA
(lane 1, 60 min at 65 °C and 10 min at 100 °C in 250 mM NaCl and
TE pH 8.0), or untreated plasmid in TE or 250 mM NaCl (lanes 5 and
6, respectively). Molecular weight markers are 10 kbp, 4 kbp, 2 kbp,
800 bp and 400 bp (lane M)
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treated samples tested negative for cytopathic effect for
FMDV and by immunohistochemical staining for CSFV,
suggesting that heat alone was sufficient in making
FMDV and CSFV non-infectious (Table 4). All safety
treated and heated samples tested negative for cyto-
pathic effect for FMDV and by immunohistochemical
staining for CSFV, indicating that the entire safety treat-
ment process (chemical treatment and heat treatment in
combination) was successful at inactivating both FMD
and CSF viruses (Table 4).
Indeed, earlier studies performed at the USDA, For-
eign Animal Disease Diagnostic Laboratory (FADDL)
previously established boiling as a method to inactivate a
number of animal disease viruses (Table 5; J. A. House,
et al., unpublished observations). Viruses tested included
African horse sickness virus (serotype 4), ASFV (Brazil
strain), FMDV (O1 Campos), lumpy skin disease virus
(Ismalia strain), porcine parvovirus (NVSL strain),
rinderpest virus (Kabete O strain), swine vesicular dis-
ease (UK 27/72 strain), vesicular exanthema of swine
(serotype A 48), and vesicular stomatitis virus (serotype
Indiana 1). Each high titer virus sample was treated by
boiling for 5 or 10 min in culture medium containing 2
to 5 % fetal bovine serum. Infectivity was assessed by in
vitro cultivation and titering in Vero, swine kidney cell
line (IBRS-2), fetal bovine lung (FBL) or swine testicular
cells (ST) depending on the virus. In all instances, boil-
ing for both 5 and 10 min were found to be effective at
eliminating infectivity as assayed by in vitro infectivity
assays. This data formed the basis for retaining a 10 min
Table 3 Effects of safety treatment on FMDV P1 cDNA sequencing applications
Sample ID Heat SCR NaOH HCl TE/ H2O P1 Sequence
1- FMD P1 cDNA heated x 0 μl 0 μl 0 μl 37 μl +
2- FMD P1 cDNA + SCR heated x 7 μl 0 μl 0 μl 30 μl +
3- FMD P1 cDNA treated x 0 μl 15 μl 15 μl 7 μl +
4- FMD P1 cDNA + SCR treated x 7 μl 15 μl 15 μl 0 μl +
5- FMD P1 cDNA diluted in H2O 0 μl 0 μl 0 μl 37 μl +
6- FMD P1 cDNA diluted salt 0 μl 15 μla 15 μla 7 μl +
7- FMD P1 cDNA control 0 μl 0 μl 0 μl 0 μl +
Samples containing various combinations of FMDV cDNA, SCR, and/or treatment conditions. FMDV sequencing results of 35 μl FMDV cDNA spanning the P1
coding region of the genome were determined to verify cDNA integrity under different treatment conditions. NaOH and heat treatment incubation time
used in this study was 60 min as optimized in previous studies. aA neutralized salt solution containing equal parts of NaOH and HCl was added instead
of individual base and acid treatments to serve as a positive control. X indicates 65 °C for 60 min and 10 min boiling steps were included, and + indicates positive
sequencing results
Fig. 3 Effects of safety treatment on FMDV cDNA by gel electrophoresis and sequencing. a RT-PCR amplified FMDV A23 Iraq P1 coding region observed
by gel electrophoresis. Untreated FMDV P1 cDNA in TE pH 8.0 (lane 1), in 250 mM NaCl (lane 2), and safety treated FMDV P1 cDNA (lane 3) are
shown. b Sequencing contig assembly chart for alkaline and heat treated FMDV P1 cDNA with sense (green) and antisense (red) sequencing
reads shown. c Sequencing contig assembly chart for untreated FMDV P1 cDNA with scale bar. Molecular weight markers are 10 kbp, 4 kbp, 2
kbp, 800 bp and 400 bp (lane M)
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boiling step following the NaOH and heat hydrolysis of
RNA as an added measure to ensure the inactivation of
the above listed animal disease viruses.
Efficacy of alkaline and heat hydrolysis treatment
After development and formalization of the protocol, the
DNA safety treatment procedure was conducted on 15
separate occasions for a total of 80 individual DNA sam-
ples. SCR rRT-PCR product was detected in two samples
near the limit of detection (Ct = 38.04 and 38.15) yielding
a specificity of 97.5 % (95 % CI ± 3.42 %) for hydrolysis of
SCR beyond the limit of rRT-PCR detection. Sensitivity of
the SCR rRT-PCR was 100 % (99 % CI ± 0 %). DNA safety
treatment of the two samples in which SCR was detectable
by rRT-PCR was repeated with complete elimination of
detectable SCR. Hence to reduce risk to a minimal level,
safety treated DNA should not be released from biocon-
tainment without a parallel control sample having a nega-
tive SCR rRT-PCR result.
Discussion
The high impact of an animal disease event associated
with the accidental release of high consequence animal
disease viruses necessitates the precaution of having
Table 4 Sample composition, treatment and virus infectivity
Sample TCID50 NaOH 65 °C Incubation NaCl Post Neutralization Boil VI FMD rRT-PCR CSF rRT-PCR
1- FMDV 6.53x104 - - - - + NT NT
2- CSFV 4.11x105 - - - - + NT NT
3- FMDV 3.51x104 - - - - + NT NT
4- CSFV 2.21x105 - - - - + NT NT
5- FMDV 3.51x104 - - 0.25 Na - + NT NT
6- CSFV 2.21x105 - - 0.25 Na - + NT NT
7- FMDV 3.51x104 - - - - + NT NT
8- CSFV 2.21x105 - - - - + NT NT
9- FMDV + SCR 2.81x104 - 60 min - 10 min - NT NT
10- CSFV + SCR 1.77x105 - 60 min - 10 min - NT NT
11- FMDV+ SCR 2.81x104 0.25 N 60 min 0.25 N 10 min - NT NT
12- CSFV + SCR 1.77x105 0.25 N 60 min 0.25 N 10 min - NT NT
13- NEG TE 0 - - - - - NT NT
14- NEG Salt 0 - - 0.25 Na - - NT NT
15- NEG Salt 0 - - 0.25 Na - - NT NT
16- NEG MEM 0 - - - - - NT NT
17- FMDV + SCR 3.98x106 - - - - + + NT
18- FMDV + SCR 3.98x106 - 60 min - - + + NT
19- FMDV + SCR 3.98x106 - - - 5 min - + NT
20- FMDV + SCR 3.98x106 - - - 10 min - + NT
21- FMDV + SCR 3.98x106 0.25 N 60 min at 25 °C 0.25 N - - - NT
22- FMDV + SCR 3.98x106 0.25 N 60 min 0.25 N 10 min - - NT
23- TE 0 - - - - - - NT
24- CSFV + SCR 2.23x104 - - - - + NT +
25- CSFV + SCR 2.23x104 - 60 min - - + NT +
26- CSFV + SCR 2.23x104 - - - 5 min - NT +
27- CSFV + SCR 2.23x104 - - - 10 min - NT +
28- CSFV + SCR 2.23x104 0.25 N 60 min at 25 °C 0.25 N - - NT +
29- CSFV + SCR 2.23x104 0.25 N 60 min 0.25 N 10 min - NT -
30- TE 0 - - - - - NT -
Samples containing various combinations of FMDV, CSFV, SCR, and treatment conditions are shown. Virus isolation (VI) results are presented to verify inactivation
of infectious FMDV and CSFV under various conditions. The NaOH and heat treatment incubation time used in this study was the optimized 60 min incubation at
65 °C. aNeutralized salt solution was added instead of NaOH. NT indicates not tested; − indicates negative rRT-PCR result or reagent or condition not added; + indi-
cates positive rRT-PCR result
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procedures to ensure the complete inactivation of vi-
ruses and + ssRNA viral genomes. In the studies
presented here, boiling alone for five minutes was dem-
onstrated to inactivate African horse sickness virus,
African swine fever virus, foot-and-mouth disease virus,
lumpy skin disease virus, porcine parvovirus, swine ves-
icular disease virus, vesicular exanthema of swine virus,
classical swine fever virus, and vesicular stomatitis virus
(Tables 4 and 5), and alkaline and heat treated samples
spiked with FMDV and CSFV likewise demonstrated loss
of virus infectivity in vitro (Table 4). The presented pro-
cedure relies not only on hot alkaline conditions (0.25 N
NaOH and 65 °C for 1 h) for the degradation of all
RNA, presumably to free ribonucleotides with 5’-hy-
droxyls and 3’-phosphates, but also on the additional
step of boiling at 100 °C for 10 min after pH has been
neutralized to between pH 7 and 8. As even a few breaks
in viral genomic RNA are likely to prevent reconstitu-
tion of infectious virus, the standard of complete loss of
rRT-PCR detectable SCR may appear to be an overly
stringent assessment for verification of the DNA safety
treatment procedure. Admittedly, the risk of animal in-
fection or accidental reconstitution and release of a virus
from RNA contaminants of purified DNA is extremely
low. Published examples of + ssRNA viruses reconsti-
tuted in animals are few and typically involve direct in-
jection of highly purified and abundant in vitro
transcribed viral RNA within a cellular transfection
medium such as lipofectamine [19, 20]. In vitro, also
using cell transfection methods, recovery of virus from
RNA is more common; though, RNA needs to be of
high quality, presumably with few or no breaks within
protein coding or regulatory elements [19, 21, 22]. It is
hoped that the stringent measure of RNA degradation
employed herein will add confidence in the safety of
exported DNA from laboratories that work with highly
infectious animal disease viruses of national and inter-
national economic impact such as FMDV.
It is also hoped that the alkaline and heat treatment
procedure will improve the quality of DNA over other
methods of DNA safety treatment such as RNAse A
treatment [23]. In this regard, NaOH and heat treatment
are expected to provide more effective degradation of
protein and/or lipid encapsulated RNA as well as RNA
within an RNA:RNA or RNA:DNA duplex. Indeed, simi-
lar treatments with NaOH and heat have been found to
be effective in removal of RNA from cDNA preparations
used in transcriptome analyses using quantitative RT-
PCR or microarrays [10, 11].
Conclusions
Although denaturation of dsDNA to ssDNA and/or nick-
ing of supercoiled plasmid DNA to relaxed covalently
closed structures is anticipated from both alkaline and
heat treatment, results of all experiments presented in this
summary demonstrated maintenance of integrity of the
DNA suitable for routine molecular biology manipulations
including PCR, rPCR, DNA sequencing, and bacterial
transformations. However, evaluation of safety treated
DNA for the potential accumulation of mutations due to
Table 5 Results of inactivation of selected viruses by boiling
Virus Species Virus Genus (Family) Cell Line Days of Incubation Virus Titers and Boiling Times (Log base 10 of TCID50 ml
−1)
0 min 5 min 10 min




Vero 10 7.7 nvd nvd









IBRS-2 3 7.5 nvd nvd



















IBRS-2 3 6.8 nvd nvd









Vero 3 5.8 nvd nvd
No virus detected (nvd); African green monkey kidney cell line (Vero); swine kidney cell line (IBRS-2); fetal bovine lung (FBL); swine testicular cell line (ST); J. A.
House, et al., unpublished observations
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error-prone DNA repair following introduction of treated
DNA to eukaryotic cells or to diverse strains of E.coli has
yet to be undertaken. One should anticipate a potential
one to two log reduction in efficiency of bacterial transfor-
mations using alkaline and heat treated plasmids, and
while treated DNA may be used directly for transforming
chemically competent E. coli, it must be desalted prior to
bacterial transformation by electroporation. Incorrect
neutralization of the alkaline conditions represents a not-
able pitfall in the DNA safety treatment procedure. This
may lead to autocatalytic depurination, DNA nicking,
dsDNA breaks or complete degradation of DNA if the
neutralization step is incorrectly performed, resulting
in acidic condition. To mitigate this, the procedure
includes a pH check of quality critical NaOH and HCl
reagents. Despite these potential technical pitfalls, alka-
line and heat hydrolysis to remove RNA from purified
DNA represents an attractive option for the safe shar-
ing of DNA between biocontainment laboratories that
work with + ssRNA viruses.
Methods
NaOH and heat safety treatment of purified DNA
Plasmid and other DNA samples ≤ 5 mg/ml buffered
with ≤ 100 mM Tris pH 8.0 or standard TE pH 8.0 are
suitable for alkaline and heat safety treatment. The DNA
safety treatment is conducted in three phases. First, po-
tential contaminating viral or bacterial agents and viral
positive sense genomic RNA that may be infectious is
destroyed by 1 h heat (65 °C and alkali treatment at
0.25 N sodium hydroxide (pH >12). Second, sample pH
is neutralized with equi-normal HCl to ensure usefulness
of DNA in downstream molecular biology applications.
Third, any potential contaminating virus present is inac-
tivated by boiling at 100 °C for 10 min. Samples are slow
cooled to room temperature for 20 min to renature DNA
prior to being stored frozen. Treated sample tubes must
remain closed after the neutralization step and throughout
the boiling step until exported from the biocontainment
lab to prevent potential post-treatment contamination.
Prior to the treatment procedure, reagents are quality
control checked for proper neutralization. Briefly, 2.33
parts by volume of TE buffer (pH 8.0), 1 part by volume
1 N NaOH and 1 part by volume of 1 N HCl are com-
bined and mixed gently. The solution is tested with a pH
meter or pH strips to ensure a proper neutralized pH
between 7 and 8.
SCR was developed as an internal control to ensure
proper degradation of contaminating RNA before ex-
portation from a containment laboratory. The SCR was
spiked into a parallel sample that was 1/5 the volume of
the primary sample. Treatment of this parallel control
sample is performed in the same manner with the same
proportions of NaOH and HCl reagents and is tested by
rRT-PCR for SCR detection along with an untreated
SCR positive control to ensure proper performance of
the procedure and effective degradation of any poten-
tially contaminating RNA.
Cells and viruses
All cell lines were supplied by the Reagent and Vaccine
Services Section (RVSS) of the USDA National Veterin-
ary Services Laboratories’ (NVSL) FADDL located at the
Plum Island Animal Disease Center (PIADC). Swine
kidney-6 (SK-6), primary lamb kidney (LK), and African
green monkey (Vero) cells were grown in Eagle’s mini-
mum essential medium (EMEM) supplemented with
10 % fetal bovine serum and incubated at 37 °C, 5 %
CO2 , and 100 % humidity. Earlier studies (J. A. House,
et al., unpublished observations) conducted in 1994
(Table 5), to assess infectivity of various viruses after
boiling for 5 and 10 min, utilized Vero, swine kidney cell
line (IBRS-2), and primary fetal bovine lung (FBL), and
swine testicular cell line (ST) cultured under similar
conditions. Virus inocula including African horse sick-
ness virus (serotype 4), African swine fever virus (Brazil
strain), FMDV (O1 Campos), lumpy skin disease virus
(Ismalia strain), porcine parvovirus (NVSL strain), rin-
derpest virus (Kabete O strain), swine vesicular disease
(UK 27/72 strain), vesicular exanthema of swine (sero-
type A 48), and vesicular stomatitis virus (serotype Indi-
ana 1) were treated by boiling for 5 or 10 min in culture
medium containing 2 to 5 % fetal bovine serum.
Viruses were supplied by the RVSS repository of the
FADDL. FMDV stocks were propagated in primary LK
cells. A cell monolayer greater than 80 % confluent was
infected with FMDV C4 Tierra del Fuego (1.0 x 107
TCID50/ml) or FMDV O Venezuela (2.51 x 10
5 TCID50/
ml) and observed for cytopathic effects (CPE) for a max-
imum of 72 h. Flasks were placed in a −70 °C freezer
when greater than 80 % of the monolayer displayed CPE.
Virus infected LK cultures were freeze-thawed, har-
vested, and stored frozen at −70 °C. Virus titrations were
performed in 96-well plates using the Spearman- Kärber
50 % tissue culture method [24]. CSFV stocks were
propagated in SK-6 cells. A cell monolayer greater than
70 % confluent was infected with CSFV Brescia (1.12 x
106 TCID50/ml) or CSFV Kanagawa (1.58 x 10
6 TCID50/
ml), incubated for 72 h, and subjected to a freeze thaw
prior to harvesting and storing at −70 °C. Virus titrations
were performed in 24-well plates and immunohisto-
chemistry was performed using the VECTASTAIN®
ABC-AP KIT according to the manufacturer instruc-
tions. ASFV Killean III (6.31 x 107 TCID50/ml) strain
was propagated in swine macrophage cells and observed
for hemadsorption (rosette formation) for a maximum
of 10 days. Flasks were freeze thawed, aliquotted, and
frozen at −70 °C until use. The 50 % tissue culture
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infectious dose using the Spearman-Kärber method was
used to calculate titrations [24].
ASFV was grown in primary cultures of peripheral
blood macrophages collected from a donor pig. Swine
macrophages were isolated from fresh whole swine
blood using a Ficoll-paque gradient and centrifugation
to separate the three phases: plasma, white blood cells
(buffy coat) and red blood cells. The buffy coat fraction
was then isolated and washed several times in RPMI/
1 % antibiotic media and plated in PRIMARIA™ coated
culture flasks. Macrophages were concentrated and
replated prior to infection and each lot was isolated
fresh for each infection. All cell lines were sterility and
virus sensitivity tested.
Virus isolation of safety treated samples
Virus isolation was performed to ensure inactivation of
FMDV and CSFV during the NaOH and heat DNA safety
treatment process. Starting titers for different stocks of
FMDV O Venezuela V3205 and CSFV Kanagawa V2861
were 2.51 x 105 TCID50/ml or 3.55 x 10
7 TCID50/ml and
1.58 x 106 TCID50/ml or 1.99 x 10
5 TCID50/ml, respect-
ively. NaOH and/or heat treatments were performed as de-
scribed below. Heating steps included incubation at 65 °C
for 1 h and boiling at 100 °C for 10 min. Various concen-
trations of virus in diluents, TE or 0.23 M NaCl (salt),
representing the final salt concentration of neutralized
NaOH treated samples, were tested with or without heat-
ing. FMDV or CSFV infectivity was assessed by in vitro
cultivation in susceptible cells in EMEM supplemented
with 4 % FBS at 37 °C, 5 % CO2, and 100 % humidity.
FMDV infectivity was assessed by cultivation in primary
LK cells in 25 cm2 polystyrene tissue culture treated flasks.
LK cells, approximately 80 % confluent, were inoculated
with 260 μl of each FMDV containing sample and observed
every 24 h post inoculation for evidence of cytopathic ef-
fects (CPE). CPE negative flasks were observed for a total
of 96 h followed by freeze-thaw and second passage on LK
cells for an additional 96 h to ensure the absence of infec-
tious FMDV. CSFV infectivity was assessed by cultivation
in SK-6 cells. SK-6 cells, approximately 70 % confluent,
were inoculated with 100 μl of each CSFV containing sam-
ple in duplicate wells of a 24-well polystyrene tissue culture
plate. At 72 h post inoculation, monolayers were fixed in
60 % acetone and 40 % methanol at −20 °C for 10 min and
stained using the VECTASTAIN® ABC-AP KIT according
to the manufacturer instructions. Stained monolayers were
evaluated microscopically to determine presence or ab-
sence of infectious CSFV.
Nucleic acids
RNA extractions for FMDV and CSFV were performed
using the RNeasy® Mini Kit (Qiagen, Valencia, CA, USA)
and DNA extractions for ASFV were performed using
the DNeasy® Blood and Tissue Kit (Qiagen, Valencia,
CA, USA) according to manufacturer’s instructions. The
pGEM-T Easy vector plasmid (Promega Corp.) was
propagated in overnight cultures of transformed JM109
or TOP10 E.coli in LB medium containing 100 μg ml−1
ampicillin. The pBlueScript II plasmid (Agilent Tech-
nologies) was similarly propagated in E.coli DH5
alpha. Plasmids were purified using the Qiagen QIA-
quick Spin Miniprep PCR Purification Kit as per
manufacturer’s instructions. Plasmid preparations were
quantified on a NanoDrop 2000 spectrophotometer
and stored frozen at −30 °C.
An internal 199 bp synthetic control RNA (SCR), de-
signed partially from the bacteriophage Q beta, was pur-






CUAAGGAUGAAAUGCAUGUC). The SCR was incor-
porated into parallel safety treatments of split samples to
ensure proper degradation of contaminating RNA before
exportation from a containment laboratory. Specific pri-
mer and probe binding sites were included in the se-
quence of the SCR for rRT-PCR detection. The SCR was
diluted in TE buffer (pH 8.0) and used at a concentra-
tion of 6 x 10−6 ng ml−1, which yields a cycle threshold
(Ct) value of 30 in rRT-PCR.
Qualitative evaluations of plasmid DNA and PCR
products before and after treatments were performed
electrophoresis in 2 % agarose gels using the E-Gel Elec-
trophoresis System (Thermo Fisher Scientific),
Bacterial transformations
Transformation efficiencies for alkali and heat treated
DNA were evaluated using competent E. coli DH5 alpha
(Invitrogen-Thermo Fisher Scientific), JM109 and
BL21(DE3) pLys S (Promega), and 60 ng alkali and heat
treated pBlueScript II plasmid (Agilent Technologies) or
untreated plasmid as control. Bacterial transformations
were performed using a variation of the heat shock
method described previously [18], prior to plating on LB
agar containing 100 μg ml−1 ampicillin, 80 μg ml−1 X-
gal, and 50 mM IPTG (Teknova). Expression and func-
tion of the LacZ gene product from pBlueScript II was
evaluated by blue white screening of DH5 alpha col-
onies, and transformation efficiencies were calculated in
colony forming units per μg of plasmid.
Real-time and conventional PCR and RT-PCR
Real-time RT-PCR was performed to optimize the
NaOH safety treatment method and to evaluate SCR
degradation, CSF RNA degradation, CSF DNA integrity,
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and ASF DNA integrity after NaOH and heat safety
treatment, heat treatment alone, and no treatment as a
control.
RNA samples were amplified using the GeneAmp® EZ
rTth RNA PCR kit (Life Technologies, Grand Island, NY,
USA) and a SmartCycler II (Cepheid, Sunnyvale, CA) with
automatic background subtraction on, or using the Taq-
Man® Fast Virus 1-Step Master Mix (Life Technologies,
Grand Island, NY, USA) and an Applied Biosystems® 7500
Real-Time PCR System (Life Technologies, Grand Island,
NY, USA). The SCR RT-PCR reactions each consisted of
0.2 μM of each primer, 0.1 μM of FAM/TAMRA probe,
5 μl of 5x GeneAmp® EZ Buffer, 5 mM of Mn(OAc)2,
1.2 mM of dNTP mix, 1 μl of rTth DNA polymerase, and
2.5 μl of RNA template in a final reaction volume of 25 μl.
The thermal profile consisted of reverse transcription at
60 °C for 10 min, followed by 45 cycles of 95 °C for 2 s and
60 °C for 30 s. Primer and probe sequences include SCR
forward primer: 5’-ACTGGGTTTTACAAACCTGTGA
-3’, SCR reverse primer: 5’- TCCGTGGCAGGACTCGC
-3’, and SCR probe: 6FAM-TCCTTTGCACGCCGTGG
GAC-TAMRA. A result cut-off, above a manual fluores-
cence threshold of 30, was defined as positive at Ct ≤ 40,
inconclusive at Ct >40, and negative if no Ct was observed.
After discontinuation of the GeneAmp® EZ rTth RNA
PCR reagents by Life Technologies, a brief methods
comparison study was performed using the TaqMan®
Fast Virus 1-Step Master Mix (Life Technologies, Grand
Island, NY, USA) to ensure reagent sensitivity similar to
the tested method. SCR rRT-PCR consisted of 0.2 μM of
each primer, 0.1 μM of FAM/TAMRA probe, 6.25 μl of
4× 1-Step Master Mix and 2.5 μl sample in a final reac-
tion volume of 25 μl. The thermal profile consisted of
reverse transcription at 50 °C for 5 min and initial
denaturation at 95 °C for 20 s, followed by 45 cycles of
95 °C for 15 s and 60 °C for 1 min.
CSFV RNA and CSFV DNA spiked pGEM Teasy vec-
tor plasmid DNA samples were amplified after NaOH
and heat treatment, heat treatment alone, and no treat-
ment as a control. Samples were amplified using the
GeneAmp® EZ rTth RNA PCR kit (Life Technologies,
Grand Island, NY, USA). The CSF rRT-PCR reactions
each consisted of 0.2 μM of each primer, 0.1 μM of
FAM/MGB probe, 5 μl of 5x GeneAmp® EZ Buffer
and 2.5 μl sample in a final reaction volume of 25 μl.
The thermal profile consisted of reverse transcription
at 60 °C for 10 min, followed by 45 cycles of 95 °C
for 2 s and 60 °C for 30 s [25].
After discontinuation of the GeneAmp® EZ rTth RNA
PCR reagents by Life Technologies, subsequent FMDV
and CSFV RNA samples were amplified using the Path-
ID™ Multiplex One-Step Kit (Life Technologies, Grand
Island, NY, USA). FMD rRT-PCR reactions consisted of
0.2 μM of each primer, 0.1 μM of FAM/TAMRA probe
[26], 12.5 μl of 2x Multiplex RT-PCR buffer, 2.5 μl of
10x Multiplex enzyme mix and 2.5 μl sample in a final
reaction volume of 25 μl. The thermal profile consisted
of reverse transcription at 48 °C for 10 min, 95 °C for
10 min, followed by 45 cycles of 95 °C for 2 s and 60 °C
for 40 s using the FAST mode on the Applied Biosys-
tems® 7500 Real-Time PCR System (Life Technologies,
Grand Island, NY, USA). CSF rRT-PCR reactions con-
sisted of 0.2 μM forward primer, 0.4 μM reverse primer,
0.2 μM of FAM/MGB probe [25], 12.5 μl of 2x Multiplex
RT-PCR buffer, 2.5 μl of 10x Multiplex enzyme mix and
2.5 μl sample in a final reaction volume of 25 μl using
the same thermal profile and platform as described
above for FMD rRT-PCR.
ASF DNA spiked pGEM Teasy vector plasmid DNA
samples were amplified after NaOH treatment and heat
treatment, heat treatment alone, and no treatment as a
control. Samples were amplified using the TaqMan® EZ
RT-PCR kit (Life Technologies, Grand Island, NY, USA).
The ASF qPCR reactions consisted of 0.3 μM of each
primer, 0.2 μM of FAM/MGB probe, 5 μl of 5x TaqMan®
EZ Buffer and 2.5 μl sample in a final reaction volume
of 25 μl. The thermal profile consisted of 45 cycles of
95 °C for 2 s and 60 °C for 30 s [27]. All rRT-PCR reac-
tions were performed on the SmartCycler II PCR plat-
form (Cepheid, Sunnyvale, CA, USA). Conventional RT-
PCR of the 3 kb capsid coding P1 region of the FMDV
genome was performed as previously described [28].
FMDV cDNA sequencing
The FMDV P1 RT-PCR product was purified using a
QIAquick® PCR Purification kit (Qiagen) according to
manufacturer’s instructions. Purified FMDV cDNA was
quantified using a NanoDrop 2000 spectrophotometer
(Fisher Scientific, Pittsburg, PA, USA) and sequenced in
10 μl reactions containing 2 μl of BigDye® Terminator
v3.1 (Applied Biosystems), 5 pmol of primer, and 15 ng
of purified RT-PCR product as previously described [28].
Thermal cycling conditions consisted of 35 cycles of 10 s
at 96 °C, 5 s at 50 °C, followed by 4 min at 60 °C. Se-
quencing products were purified on a Kingfisher 96
magnetic particle processor (Thermo Fisher Scientific)
using a high-throughput the CleanSEQ kit (Agencourt).
Nucleotide sequences were resolved using a 3730XL
DNA sequencer (Applied Biosystems), and sequence
contigs for each sample were compiled using the
Sequencher® software (Gene Codes).
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